Research News

Apaxaban and warfarin go head to head in selected adults with venous thromboembolism

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4292 (Published 03 July 2013) Cite this as: BMJ 2013;347:f4292

This article has a correction. Please see:

Apaxaban is a direct inhibitor of factor Xa and a potential alternative to warfarin for the treatment of acute venous thromboembolism. The two manufacturers’ latest trial tested apaxaban against conventional treatment with subcutaneous enoxaparin followed by warfarin in more than 5000 patients with an acute unprovoked and symptomatic thromboembolic …

View Full Text

Sign in

Log in through your institution

Subscribe